***TASK***
the task is to simplify the input abstract of a biomedical literature

***INPUT***
the input is the abstract of a biomedical literature

***OUTPUT***
the output is the simplified abstract for the input abstract of a biomedical literature

***DOCUMENTATION***

***EXAMPLES***

Input: Seven studies were found to be suitable for inclusion from 33 identified as relevant. None of the trials provided adequate evidence to support the use of hydroxyurea owing to small sample size, large numbers of post-randomisation exclusions and questionable rules for censoring, particularly a failure to include treatment-related deaths in the survival analysis. Details of statistical analysis were limited and often confusing, and we felt meta-analysis would lead to unreliable and invalid conclusions. Most studies appeared to be double blind placebo-controlled studies but none give details of power calculations or reasons for stopping recruitment. Only two studies had more than 50 patients. Patients were excluded from analysis in most trials for treatment-related reasons; in one, less than half those recruited were used in the analysis, the remainder having been excluded because of tumour progression or treatment-related conditions e.g. septicaemia, worsening renal/hepatic function. In another trial five out of 20 in the hydroxyurea group died of treatment-related complications but the five-year survival group was presented as 94%. We found no evidence to support the use of hydroxyurea in addition to radiotherapy in the routine treatment of cervix cancer.
Output:

The orally-administered cytotoxic, hydroxyurea, may be given alongside radiotherapy for treating cervix cancer. Eight trials comparing concomitant hydroxyurea and radiotherapy with radiotherapy alone were assessed. They were not of sufficient quality to be able to pool the data. Although several trials reported an improvement in survival for patients receiving hydroxyurea, this conclusion was unreliable owing to methodological problems associated with trials including small sample size, a large number of patients excluded from analysis and questionable methods of analysis such as exclusion of treatment related deaths.